Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 (Study)

The LDN Conference 2021: 4th - 6th June 2021

Up to 29 CME Credits Available + Sponsor, Exhibitor and Advertiser Opportunities.  [More Details]

Submitted by baileylynn_100964 on Tue, 03/30/2021 - 05:52

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

ClinicalTrial.gov
28 April 2020
https://clinicaltrials.gov/ct2/show/NCT04365985

Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
 

Type of Video